Abstract
Objective:
This study aimed to systematically evaluate the efficacy of first-line immune checkpoint inhibitors (ICIs) combined with targeted therapy for advanced renal cell carcinoma (RCC) and assess their cost-effectiveness from the perspective of the Chinese healthcare system.
Methods:
Phase III randomized controlled trials comparing ICI-targeted combinations versus sunitinib as first-line treatment for advanced RCC were identified through systematic searches of PubMed, EMBASE, and the Cochrane Library. A network meta-analysis (NMA) was performed to compare the hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) among different regimens. The surface under the cumulative ranking curve (SUCRA) was calculated to rank treatment efficacy. Based on the NMA results, a partitioned survival model was developed for the cost-effectiveness analysis. Using the sunitinib arm from the CheckMate 9ER trial as the reference, parametric survival models were fitted to extrapolate survival outcomes over a 20-year time horizon. HRs from the NMA were applied to derive survival curves for other interventions. The model cycle length was 6 weeks. Costs included drug acquisition, follow-up, adverse event management, subsequent therapy, and palliative care. Utility values were sourced from published literature. An incremental cost-effectiveness ratio (ICER) was calculated against a willingness-to-pay (WTP) threshold of $40,332.35 per quality-adjusted life-year (QALY). Sensitivity and scenario analyses were conducted.
Results:
Seven trials involving 4,973 patients were included. The NMA showed that pembrolizumab plus lenvatinib ranked highest for PFS, whereas toripalimab plus axitinib ranked highest for OS. The cost-effectiveness analysis indicated that toripalimab plus axitinib yielded the greatest gains in life-years and QALYs, with the lowest ICER of $62,204.37 among all evaluated strategies. However, all regimens exceeded the WTP threshold of $40,332.35 per QALY. Sensitivity analyses confirmed the robustness of these findings.
Conclusion:
This study demonstrates that while toripalimab plus axitinib is the most efficacious first-line regimen for aRCC and offers the lowest ICER, none of the evaluated regimens are economically viable from the perspective of the Chinese healthcare system at the WTP threshold of $40,332.35 per QALY.
Systematic review registration:
https://www.crd.york.ac.uk/PROSPERO/view/CRD420261503119, identifier CRD420261503119.
1 Introduction
According to the 2022 GLOBOCAN report (), kidney cancer ranks as the 14th most commonly diagnosed cancer and the 16th leading cause of cancer death worldwide. Pathologically, renal cell carcinoma (RCC) constitutes the predominant histological subtype of kidney cancer (). In 2022, there were an estimated 73,700 new cases of renal cell carcinoma (RCC) in China. This number accounted for 1.5% of all new cancer cases. The estimated number of deaths caused by RCC was 24,000. This figure represented 0.9% of all cancer deaths in the country ().
The prognosis of advanced renal cell carcinoma (aRCC) has improved markedly over the past decade due to advances in therapeutic modalities, yet it remains a challenging disease overall. For patients with aRCC, sunitinib was historically used as standard therapy (). Although targeted agentsāsuch as vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs)āhave constituted the first-line standard for aRCC for the past decade, the current treatment paradigm has shifted toward immune-based combinations. In recent years, targeted-immunotherapy combinations have become the first-line standard for aRCC (, ). For instance, the combination of axitinib and toripalimab extended the median progression-free survival (mPFS) from 9.8 months to 18.0 months () and reduced the risk of death by 39%. Additionally, the combination of nivolumab and cabozantinib achieved a median overall survival (mOS) of 45.3 months (). However, head-to-head randomized controlled trials directly comparing all these regimens are lacking. Therefore, a network meta-analysis (NMA) is required to perform indirect comparisons of their relative efficacy in the absence of direct evidence, thereby providing evidence for clinical decision-making.
Although these novel immune-targeted combination therapies demonstrate satisfactory efficacy, they incur extremely high costs and impose a substantial economic burden on patients and healthcare systems. In the context of limited medical resources, especially in upper-middle-income countries such as China, evidence of clinical efficacy alone is insufficient to justify widespread clinical application. Therefore, it is necessary to evaluate the cost-effectiveness of these regimens from a health economics perspective. This assessment can provide critical supplementary evidence for medical insurance policymaking, hospital management, and individualized treatment decisions by clinicians.
In summary, this study aims to systematically compare the efficacy of different first-line immunotherapy plus targeted therapy combinations for aRCC through NMA. On this basis, a cost-effectiveness analysis of the optimal treatment regimens will be conducted from the perspective of Chinaās healthcare system. The findings intend to offer comprehensive evidence for clinical practice and the rational allocation of health resources.
2 Methods
2.1 Network meta-analysis
2.1.1 Search strategy
We conducted the NMA in accordance with the PRISMA guidelines (Supplementary Table S1) (). We systematically searched PubMed, EMBASE, and the Cochrane Library to identify phase III randomized controlled trials (RCTs) evaluating first-line combinations of immune checkpoint inhibitors (ICIs) with targeted agents for patients with aRCC. The search was conducted from inception until March 1, 2026. We also manually searched conference abstracts from major international oncology meetings, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the American Association for Cancer Research (AACR) (Supplementary Methods).
2.1.2 Study screening and data extraction
The study selection process was conducted independently by two investigators to minimize bias. Initially, all records retrieved from the database searches were imported into reference management software (EndNote X9), and duplicates were removed automatically and manually. Subsequently, the titles and abstracts of the remaining records were screened against the pre-defined eligibility criteria (Supplementary Table S2). The full texts of all potentially relevant articles were then obtained and assessed in detail. Any disagreements between the two reviewers at any stage of the screening process were resolved through discussion or by consultation with a third senior investigator if necessary. The entire screening process was documented and presented in a PRISMA flow diagram (Supplementary Figure S1).
Data from the included studies were extracted independently by the same two investigators using a standardized, pilot-tested data extraction form developed in Microsoft Excel. The extracted information included: first author, publication year, clinical trial registration number, study phase, design, sample size, drugs, hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) and incidence of grade ā„3 adverse events.
2.1.3 Risk of bias assessment
The risk of bias in the included randomized controlled trials was assessed independently by two investigators using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2.0).
2.1.4 Synthesis of data and statistical analysis
The relative efficacy of all first-line treatment regimens was evaluated using a network meta-analysis. All NMA procedures were performed using R software (version 4.4.2) with the gemtc package. A fixed-effect model was used because each direct treatment comparison was based on a single phase III randomized controlled trial and between-study heterogeneity could not be estimated. Therefore, I² and ϲ were not available. The evidence network was star-shaped, with sunitinib as the common comparator, and no closed loops were present. Accordingly, node-splitting and other loop-based consistency assessments were not applicable (, ). The network structure is shown in FigureĀ 1. The hierarchy of treatments was evaluated by calculating the surface under the cumulative ranking (SUCRA) curve for each intervention, representing the probability of it being the most effective option.
FigureĀ 1
2.2 Cost-effectiveness analysis
2.2.1 Model structure
This cost-effectiveness analysis followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist (Supplementary Table S3) (). A three-state partitioned survival model (FigureĀ 2) was developed to estimate the long-term clinical and economic outcomes of the evaluated first-line strategies. The model comprised PFS, progressed disease (PD), and death. At model entry, all patients were assumed to be in the PFS state. The model used a 6-week cycle, consistent with the treatment administration schedule. The analysis was conducted over a 20-year time horizon to capture long-term outcomes because this time horizon can capture the majority of patientsā survival events. An annual discount rate of 5% was applied to both future costs and health outcomes (). The impact of the discount rate was further examined in the sensitivity analysis.
FigureĀ 2
2.2.2 Clinical data inputs
Clinical inputs were obtained from the included trials and the NMA. The sunitinib arm of CheckMate 9ER was used as the reference survival source because this trial provided relatively mature follow-up data (). The uncertainty associated with the selection of CheckMate 9ER as the baseline survival source was further examined in scenario analyses using the sunitinib arms from alternative phase III trials. Published K-M curves for the sunitinib arm of CheckMate 9ER were digitized using GetData Graph Digitizer (v2.26) to obtain survival coordinates. Pseudo-individual patient data were then reconstructed in R (v4.4.2) and fitted using a range of candidate survival models, including exponential, Weibull, gamma, generalized gamma, Gompertz, log-logistic, log-normal, and Royston-Parmar (RP) spline models (, ). The optimal parametric distribution was determined based on the Akaike information criterion (AIC) and Bayesian information criterion (BIC), with lower values indicating a better fit (). Model fit was further assessed by visual comparison of the fitted and observed survival curves (Supplementary Figures S2āS15). AIC values and BIC values were shown in Supplementary Table S4 and the survival parameters for selected model were shown in Supplementary Table S5. For the remaining ICI-targeted regimens, long-term survival was estimated by applying the NMA-derived HRs as exponents to the fitted sunitinib survival curve. After disease progression, everolimus was assumed as the subsequent treatment, with the proportion receiving second-line therapy obtained from the corresponding clinical trials (). The impact of this assumption was examined in scenario analyses using alternative subsequent-treatment regimens.
2.2.3 Cost and utility
Only direct medical costs were considered from the perspective of the Chinese healthcare system. These included drug acquisition costs, supportive treatment, routine follow-up, subsequent therapy, terminal care cost, and management of treatment-related adverse events (AEs). A patient body weight of 65kg was assumed for calculating drugs dosing (). The utility values for the health states of PFS, PD, and death were set at 0.78, 0.66, and 0 respectively (). All input parameters and distributions are detailed in TableĀ 1 (, , , , ā).
TableĀ 1
| Parameter | Base-line value | Range | Reference | |
|---|---|---|---|---|
| Lower bound | Upper bound | |||
| Cost values (US $) | ||||
| Sunitinib per 12.5mg | 2.53 | 1.90 | 3.16 | Local charge |
| Atezolizumab per 1200mg | 4605.45 | 3454.09 | 5756.81 | Local charge |
| Bevacizumab per 100mg | 139.29 | 104.47 | 174.11 | Local charge |
| Avelumab per 10mg | 81.74 | 61.31 | 102.18 | () |
| Axitinib per 1 mg | 8.05 | 6.04 | 10.07 | Local charge |
| Benmelstobart per 600 mg | 1724.23 | 1293.18 | 2155.29 | Local charge |
| Anlotinib per 12mg | 39.81 | 29.85 | 49.76 | Local charge |
| Nivolumab per 40mg | 644.02 | 483.02 | 805.03 | Local charge |
| Cabozantinib per 60mg | 491.30 | 368.47 | 614.12 | () |
| Ipilimumab per 50mg | 2527.38 | 1895.53 | 3159.22 | Local charge |
| Pembrolizumab per 100mg | 2515.87 | 1886.90 | 3144.83 | Local charge |
| Lenvatinib per 4mg | 1.19 | 0.89 | 1.49 | Local charge |
| Toripalimab per 240mg | 264.65 | 198.49 | 330.82 | Local charge |
| Everolimus per 2.5mg | 6.78 | 5.09 | 8.48 | Local charge |
| Routine follow-up per cycle | 442.30 | 331.725 | 552.875 | () |
| Best supportive care per cycle | 92.23 | 69.1725 | 115.2875 | () |
| Terminal care per event | 1893.00 | 1419.75 | 2366.25 | () |
| Increased lipase per event | 0 | 0 | 0.00 | () |
| Hypertension per event | 12.61 | 9.46 | 15.76 | () |
| Diarrhea per event | 43.3 | 32.48 | 54.13 | () |
| Platelet count decreased per event | 254.02 | 190.52 | 317.53 | () |
| White blood cell decreased per event | 89 | 66.92 | 111.54 | () |
| ALT increased per event | 25.09 | 18.82 | 31.36 | () |
| Anemia per event | 508.2 | 381.15 | 635.25 | () |
| Proteinuria per event | 121.65 | 91.24 | 152.06 | () |
| Utility values | ||||
| PFS | 0.78 | 0.585 | 0.975 | () |
| PD | 0.66 | 0.495 | 0.825 | () |
| Probability of SAEs in Sunitinib group | ||||
| Hypertension | 0.212 | 0.159 | 0.265 | () |
| Platelet count decreased | 0.239 | 0.179 | 0.298 | () |
| White blood cell decreased | 0.117 | 0.088 | 0.147 | () |
| Probability of SAEs in Pembrolizumab plus Lenvatinib group | ||||
| Diarrhea | 0.111 | 0.083 | 0.139 | () |
| Hypertension | 0.290 | 0.217 | 0.362 | () |
| Probability of SAEs in Nivolumab plus Cabozantinib group | ||||
| Hypertension | 0.131 | 0.098 | 0.164 | () |
| Probability of SAEs in Avelumab + Axitinib group | ||||
| Hypertension | 0.277 | 0.207 | 0.346 | () |
| Probability of SAEs in Benmelstobart plus Anlotinib group | ||||
| Hypertension | 0.345 | 0.259 | 0.431 | () |
| Platelet count decreased | 0.008 | 0.006 | 0.010 | () |
| White blood cell decreased | 0.008 | 0.006 | 0.010 | () |
| Probability of SAEs in Atezolizumab plus Bevacizumab group | ||||
| Hypertension | 0.140 | 0.105 | 0.175 | () |
| Probability of SAEs in Pembrolizumab plus Axitinib group | ||||
| Diarrhoea | 0.107 | 0.080 | 0.134 | () |
| Hypertension | 0.221 | 0.166 | 0.277 | () |
| ALT increased | 0.126 | 0.094 | 0.157 | () |
| Probability of SAEs in Toripalimab plus Axitinib group | ||||
| Neutropenia | 0.111 | 0.083 | 0.138 | () |
| Anemia | 0.154 | 0.115 | 0.192 | () |
| Thrombocytopenia | 0.289 | 0.216 | 0.361 | () |
| Leukopenia | 0.010 | 0.007 | 0.012 | () |
| Neutrophil count decreased | 0.000 | 0.000 | 0.000 | () |
| Proportion of patients received second-line therapy | ||||
| Sunitinib group | 0.554 | 0.416 | 0.693 | () |
| Pembrolizumab + Lenvatinib group | 0.510 | 0.382 | 0.637 | () |
| Nivolumab + Cabozantinib group | 0.431 | 0.324 | 0.539 | () |
| Avelumab + Axitinib group | 0.581 | 0.436 | 0.727 | () |
| Benmelstobart + Anlotinib group | 0.258 | 0.193 | 0.322 | () |
| Atezolizumab + Bevacizumab group | 0.425 | 0.319 | 0.531 | () |
| Pembrolizumab + Axitinib group | 0.549 | 0.411 | 0.686 | () |
| Toripalimab + Axitinib group | 0.162 | 0.121 | 0.202 | () |
| Other | ||||
| Discount rate | 5% | 0% | 8% | () |
| Body weight | 65.00 | 48.75 | 81.25 | () |
Model input parameters and ranges used in the sensitivity analysis.
2.2.4 Base case analysis
Effectiveness was expressed in quality-adjusted life years (QALYs). All costs were converted to 2024 U.S. dollars using an exchange rate of US $1 = CNY 7.122, and both costs and health outcomes were discounted annually at 5%. Cost-effectiveness was evaluated using the ICER, with a WTP threshold of $40,332.35 per QALY based on the World Health Organization (WHO) recommendations () and China guidelines for pharmacoeconomic evaluations (). Cost and utility parameters were shown in TableĀ 1.
2.2.5 Sensitivity analysis
Uncertainty in the model outcomes was explored through one-way and probabilistic sensitivity analyses. In the one-way analysis, individual parameters were varied by ±25% from their base-case values, and the resulting changes in the ICER were summarized using a tornado diagram. For the probabilistic analysis, 1,000 Monte Carlo simulations were performed to generate cost-effectiveness acceptability curves. Cost-effectiveness probabilities were evaluated at WTP thresholds of $13,444.12, $26,888.23, and $40,332.35 per QALY, corresponding to 1, 2, and 3 times Chinaās 2024 per capita GDP, respectively. For this analysis, cost data were assigned a gamma distribution, while utility values and adverse event incidence rates were assigned beta distributions.
2.2.6 Scenario analysis
Several scenario analyses were conducted to assess uncertainty related to key model assumptions. Alternative baseline survival scenarios were examined using the sunitinib arms from CLEAR, JAVELIN Renal 101, IMmotion151, KEYNOTE-426, ETER100, and RENOTORCH instead of CheckMate 9ER. For each alternative baseline, PFS and OS curves were reconstructed from the published KaplanāMeier curves and fitted independently using the candidate survival models described above. Model selection was primarily based on the lowest AIC, supplemented by visual inspection of the fitted curves and the clinical plausibility of long-term extrapolation (Supplementary Figures S2āS15). All other model inputs were kept unchanged.
Alternative subsequent-treatment scenarios were evaluated to assess the impact of the base-case assumption of everolimus after disease progression. Pazopanib, sorafenib, and vorolanib plus everolimus were considered as alternative subsequent treatments. Only subsequent-treatment costs were changed in these scenarios, while survival outcomes and other model inputs remained unchanged.
To explore the potential effect of future drug-price negotiations in China, price reductions of 20%, 40%, and 60% were applied to drugs not included in the 2025 National Reimbursement Drug List (NRDL) (). For regimens containing two non-NRDL drugs, the prices of both agents were reduced by the same proportion, whereas the prices of NRDL-listed drugs were kept unchanged.
A price-threshold analysis was performed to estimate the minimum price reduction required for each combination regimen to become cost-effective. In this analysis, the prices of both drugs within each combination regimen were assumed to decrease simultaneously by the same proportion, irrespective of their current NRDL status, until the ICER reached the prespecified WTP threshold of $40,332.35 per QALY.
3 Results
3.1 Network meta-analysis results
A total of 14,688 records were initially identified through database searches. After the selection process (Supplementary Figure S1), 7 trials (, , ā) (CLEAR, CheckMate 9ER, JAVELIN Renal 101, ETER-100, IMmotion151, KEYNOTE-426, RENOTORCH) were included in the NMA. Supplementary Table S6 summarizes the characteristics of these trials. The overall risk of bias for the included studies is summarized in Supplementary Figure S16. The HRs for each treatment regimen are presented in TableĀ 2. For PFS, pembrolizumab plus lenvatinib showed the highest SUCRA ranking, whereas toripalimab plus axitinib ranked highest for OS (FiguresĀ 3A, B).
TableĀ 2
| Overall survival | |||||||
|---|---|---|---|---|---|---|---|
| Treatment | Ate+Bev | Ava+Axi | Ben+Anl | Nivo+Cabo | Pem+Axi | Pem+Len | Tori+Axi |
| Ate+Bev | 1 | 0.97 (0.76ā1.23) | 0.72 (0.50ā1.05) | 0.87 (0.67ā1.12) | 0.93 (0.72ā1.18) | 0.87 (0.65ā1.15) | 0.67 (0.43ā1.05) |
| Ava+Axi | 1.03 (0.81ā1.31) | 1 | 0.75 (0.52ā1.08) | 0.90 (0.69ā1.16) | 0.95 (0.76ā1.20) | 0.90 (0.68ā1.19) | 0.69 (0.44ā1.09) |
| Ben+Anl | 1.38 (0.95ā2.00) | 1.33 (0.93ā1.92) | 1 | 1.19 (0.82ā1.75) | 1.27 (0.88ā1.82) | 1.19 (0.81ā1.79) | 0.93 (0.54ā1.56) |
| Nivo+Cabo | 1.15 (0.89ā1.50) | 1.11 (0.86ā1.44) | 0.84 (0.57ā1.22) | 1 | 1.06 (0.82ā1.37) | 1.00 (0.74ā1.35) | 0.77 (0.49ā1.22) |
| Pem+Axi | 1.08 (0.85ā1.38) | 1.05 (0.83ā1.32) | 0.79 (0.55ā1.13) | 0.94 (0.73ā1.22) | 1 | 0.94 (0.71ā1.25) | 0.72 (0.46ā1.14) |
| Pem+Len | 1.15 (0.87ā1.53) | 1.11 (0.84ā1.47) | 0.84 (0.56ā1.24) | 1.00 (0.74ā1.35) | 1.06 (0.80ā1.41) | 1 | 0.77 (0.48ā1.23) |
| Tori+Axi | 1.49 (0.95ā2.34) | 1.44 (0.92ā2.26) | 1.08 (0.64ā1.84) | 1.30 (0.82ā2.05) | 1.38 (0.88ā2.16) | 1.30 (0.81ā2.08) | 1 |
| Progression-Free survival | |||||||
| Treatment | Ate+Bev | Ava+Axi | Ben+Anl | Nivo+Cabo | Pem+Axi | Pem+Len | Tori+Axi |
| Ate+Bev | 1 | 0.79 (0.64ā0.99) | 0.64 (0.48ā0.85) | 0.70 (0.55ā0.89) | 0.83 (0.66ā1.04) | 0.56 (0.44ā0.74) | 0.78 (0.56ā1.09) |
| Ava+Axi | 1.26 (1.01ā1.57) | 1 | 0.80 (0.61ā1.06) | 0.88 (0.69ā1.11) | 1.04 (0.84ā1.30) | 0.71 (0.55ā0.92) | 0.98 (0.71ā1.35) |
| Ben+Anl | 1.57 (1.18ā2.08) | 1.25 (0.94ā1.65) | 1 | 1.10 (0.81ā1.47) | 1.30 (0.98ā1.72) | 0.88 (0.65ā1.20) | 1.22 (0.85ā1.75) |
| Nivo+Cabo | 1.43 (1.12ā1.82) | 1.14 (0.90ā1.44) | 0.91 (0.68ā1.23) | 1 | 1.19 (0.93ā1.52) | 0.82 (0.62ā1.06) | 1.12 (0.81ā1.56) |
| Pem+Axi | 1.20 (0.96ā1.51) | 0.96 (0.77ā1.19) | 0.77 (0.58ā1.02) | 0.84 (0.66ā1.07) | 1 | 0.68 (0.53ā0.88) | 0.94 (0.68ā1.30) |
| Pem+Len | 1.77 (1.36ā2.29) | 1.40 (1.09ā1.81) | 1.13 (0.83ā1.54) | 1.22 (0.94ā1.62) | 1.47 (1.14ā1.90) | 1 | 1.39 (0.98ā1.96) |
| Tori+Axi | 1.28 (0.92ā1.77) | 1.02 (0.74ā1.40) | 0.82 (0.57ā1.18) | 0.89 (0.64ā1.24) | 1.06 (0.77ā1.47) | 0.72 (0.51ā1.02) | 1 |
Hazard ratios of the network meta-analysis of the progression-free survival and overall survival.
Ate, Atezolizumab; Bev, Bevacizumab; Ava, Avelumab; Axi, Axitinib; Ben, Benmelstobart; Anl, Anlotinib; Nivo, Nivolumab; Cabo, Cabozantinib; Ipi, Ipilimumab; Pem, Pembrolizumab; Len, Lenvatinib; Sun, Sunitinib; Tori, Toripalimab.
FigureĀ 3
3.2 Cost-effectiveness analysis results
3.2.1 Base-case analysis results
From the perspective of the Chinese healthcare system and over a 20-year timeframe, the combination of toripalimab and axitinib provided the greatest gain in QALYs. Base-case analysis revealed that none of the evaluated first-line regimens were deemed cost-effective at the Chinese WTP threshold of $40,332.35 per QALY. Among all ICI plus targeted therapy regimens, toripalimab plus axitinib demonstrated the lowest ICER at $62,204.37 per QALY gained, yet it still exceeded the predefined threshold. Detailed results of the base-case analysis are presented in TableĀ 3.
TableĀ 3
| Treatment | Costs ($) | QALYs | Incremental cost ($) | Incremental QALYs | ICER ($/QALY) |
|---|---|---|---|---|---|
| Sunitinib | 108691.1057 | 3.9749 | NA | NA | NA |
| Toripalimab + Axitinib | 214070.9886 | 5.6690 | 105379.8829 | 1.6941 | 62204.3704 |
| Atezolizumab + Bevacizumab | 310112.0995 | 4.3187 | 201420.9938 | 0.3438 | 585810.0613 |
| Benmelstobart + Anlotinib | 354575.3268 | 5.5053 | 245884.2212 | 1.5304 | 160662.8444 |
| Pembrolizumab + Axitinib | 409960.3006 | 4.6320 | 301269.1949 | 0.6571 | 458461.2052 |
| Pembrolizumab + Lenvatinib | 417349.3324 | 4.9891 | 308658.2267 | 1.0142 | 304325.3285 |
| Avelumab + Axitinib | 533928.9403 | 4.5006 | 425237.8346 | 0.5257 | 808897.9354 |
| Nivolumab + Cabozantinib | 952227.5316 | 4.8945 | 843536.4259 | 0.9196 | 917315.6286 |
Base-case analysis results.
LYs, Life-years; QALYs, Quality-adjusted life-years; ICER, Incremental cost-effectiveness ratio.
3.2.2 Sensitivity analysis results
Drawing on the findings of the base-case analysis, one-way sensitivity analyses were conducted on key parameters for toripalimab plus axitinib versus sunitinib (FigureĀ 4). The one-way sensitivity analysis showed that the discount rate was the most influential parameter, followed by the cost of axitinib and the utility values of the PFS and PD states. These parameters produced the largest variations in the ICER, whereas the remaining parameters had relatively limited effects. Probabilistic sensitivity analyses showed consistently low probabilities of cost-effectiveness across WTP thresholds corresponding to 1, 2, and 3 times Chinaās per capita GDP (FigureĀ 5). Even at the highest threshold of $40,332.35 per QALY (3 times per capita GDP), no regimen achieved a cost-effectiveness probability exceeding 2%. Toripalimab plus axitinib had the most favorable economic performance among the evaluated regimens, with a base-case ICER of $62,204.37 per QALY and a cost-effectiveness probability of approximately 2% at this threshold. This confirms that, despite offering the greatest health benefits, none of the regimens represented an economically viable option for the Chinese healthcare system at current pricing levels.
FigureĀ 4
FigureĀ 5
3.2.3 Scenario analysis results
The alternative baseline survival scenarios resulted in some variation in estimated costs, QALYs, and ICERs, but did not change the overall cost-effectiveness conclusions. For toripalimab plus axitinib, the ICER ranged from approximately $65,595 to $108,640 per QALY across the alternative baseline survival scenarios, compared with $62,204.37 per QALY in the base case. The largest deviation was observed when the RENOTORCH sunitinib arm was used as the baseline survival source. None of the evaluated regimens was cost-effective at the WTP threshold of $40,332.35 per QALY under any alternative baseline assumption (Supplementary Table S7).
Changes in subsequent-treatment assumptions affected total costs and ICERs, while QALYs remained unchanged. For toripalimab plus axitinib, the ICER was $57,026.85 per QALY under the pazopanib scenario, $68,132.11 per QALY under the sorafenib scenario, and $56,900.05 per QALY under the vorolanib plus everolimus scenario. The overall cost-effectiveness conclusions remained unchanged across the alternative subsequent-treatment scenarios (TableĀ 4).
TableĀ 4
| Treatment regimen | Drug(s) subject to price reduction | Base-case ICER ($/QALY) | 20% price reduction | 40% price reduction | 60% price reduction |
|---|---|---|---|---|---|
| Pembrolizumab + Lenvatinib | Pembrolizumab | 304325.3285 | 240336.8842 | 176348.4398 | 112359.9955 |
| Nivolumab + Cabozantinib | Nivolumab + Cabozantinib | 917315.6286 | 849640.6730 | 545570.3541 | 359697.7169 |
| Avelumab + Axitinib | Avelumab | 808897.9354 | 672187.1952 | 535476.4549 | 398765.7147 |
| Benmelstobart + Anlotinib | Benmelstobart | 160662.8444 | 134954.612 | 109246.3796 | 83538.14716 |
| Atezolizumab + Bevacizumab | Atezolizumab | 585810.0613 | 492167.9312 | 398525.8011 | 304883.6709 |
| Pembrolizumab + Axitinib | Pembrolizumab | 458461.2052 | 392708.3469 | 326955.4886 | 261202.6304 |
Results of NRDL-related price-reduction scenario analysis.
Reducing the prices of non-NRDL drugs by 20%, 40%, and 60% progressively lowered the ICERs of the corresponding regimens. However, none of the evaluated regimens became cost-effective even when the prices of non-NRDL drugs were reduced by 60% (TableĀ 5).
TableĀ 5
| Treatment regimen | Drugs subject to simultaneous price reduction | Required simultaneous price reduction to reach WTP |
|---|---|---|
| Pembrolizumab + Lenvatinib | Pembrolizumab + Lenvatinib | 92.8% |
| Nivolumab + Cabozantinib | Nivolumab + Cabozantinib | 98.7% |
| Avelumab + Axitinib | Avelumab + Axitinib | 97.6% |
| Benmelstobart + Anlotinib | Benmelstobart + Anlotinib | 80.6% |
| Atezolizumab + Bevacizumab | Atezolizumab + Bevacizumab | 90.0% |
| Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | 95.2% |
| Toripalimab + Axitinib | Toripalimab + Axitinib | 41.5% |
Results of price-threshold analysis.
The price-threshold analysis showed that the simultaneous price reductions required for the combination regimens to reach the WTP threshold ranged from 41.5% to 98.7% (TableĀ 6). Toripalimab plus axitinib required the smallest price reduction, at 41.5%, whereas nivolumab plus cabozantinib required the largest reduction, at 98.7%. All other regimens required price reductions of more than 80% to achieve cost-effectiveness.
TableĀ 6
| Treatment regimen | Total cost (US$) | Incremental cost (US$) | QALYs | Incremental QALYs | ICER (US$/QALY) |
|---|---|---|---|---|---|
| Second-line scenario: Pazopanib | |||||
| Sunitinib | 123,009.48 | NA | 3.9749 | NA | NA |
| Toripalimab + Axitinib | 219,618.17 | 96,608.68 | 5.6690 | 1.6941 | 57,026.85 |
| Atezolizumab + Bevacizumab | 321,202.63 | 198,193.14 | 4.3187 | 0.3438 | 576,422.23 |
| Benmelstobart + Anlotinib | 361,577.76 | 238,568.27 | 5.5053 | 1.5304 | 155,882.54 |
| Pembrolizumab + Axitinib | 423,858.30 | 300,848.81 | 4.6320 | 0.6571 | 457,821.48 |
| Pembrolizumab + Lenvatinib | 426,737.61 | 303,728.12 | 4.9891 | 1.0142 | 299,464.43 |
| Avelumab + Axitinib | 547,286.39 | 424,276.91 | 4.5006 | 0.5257 | 807,070.04 |
| Nivolumab + Cabozantinib | 962,411.73 | 839,402.25 | 4.8945 | 0.9196 | 912,819.86 |
| Second-line scenario: Sorafenib | |||||
| Sunitinib | 92,298.02 | NA | 3.9749 | NA | NA |
| Toripalimab + Axitinib | 207,720.03 | 115,422.01 | 5.6690 | 1.6941 | 68,132.11 |
| Atezolizumab + Bevacizumab | 297,414.58 | 205,116.55 | 4.3187 | 0.3438 | 596,558.17 |
| Benmelstobart + Anlotinib | 346,558.26 | 254,260.23 | 5.5053 | 1.5304 | 166,135.80 |
| Pembrolizumab + Axitinib | 394,048.51 | 301,750.49 | 4.6320 | 0.6571 | 459,193.62 |
| Pembrolizumab + Lenvatinib | 406,600.71 | 314,302.69 | 4.9891 | 1.0142 | 309,890.56 |
| Avelumab + Axitinib | 518,636.02 | 426,338.00 | 4.5006 | 0.5257 | 810,990.69 |
| Nivolumab + Cabozantinib | 940,567.66 | 848,269.64 | 4.8945 | 0.9196 | 922,462.83 |
| Second-line scenario: Vorolanib + Everolimus | |||||
| Sunitinib | 123,360.14 | NA | 3.9749 | NA | NA |
| Toripalimab + Axitinib | 219,754.02 | 96,393.88 | 5.6690 | 1.6941 | 56,900.05 |
| Atezolizumab + Bevacizumab | 321,474.23 | 198,114.09 | 4.3187 | 0.3438 | 576,192.32 |
| Benmelstobart + Anlotinib | 361,749.25 | 238,389.11 | 5.5053 | 1.5304 | 155,765.47 |
| Pembrolizumab + Axitinib | 424,198.66 | 300,838.52 | 4.6320 | 0.6571 | 457,805.81 |
| Pembrolizumab + Lenvatinib | 426,967.53 | 303,607.39 | 4.9891 | 1.0142 | 299,345.39 |
| Avelumab + Axitinib | 547,613.51 | 424,253.38 | 4.5006 | 0.5257 | 807,025.28 |
| Nivolumab + Cabozantinib | 962,661.14 | 839,301.00 | 4.8945 | 0.9196 | 912,709.76 |
Scenario analyses under alternative second-line treatment assumptions.
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; NA, not applicable.
4 Discussion
This study provides an updated integrated assessment of the comparative efficacy and cost-effectiveness of first-line ICI plus targeted therapy regimens for aRCC. Our NMA showed that pembrolizumab plus lenvatinib achieved the highest SUCRA ranking for PFS, whereas toripalimab plus axitinib ranked highest for OS. These findings suggest that treatment selection in clinical practice should consider different therapeutic objectives. Pembrolizumab plus lenvatinib may be preferred when delaying disease progression is a major treatment goal, whereas toripalimab plus axitinib may represent a promising option when long-term survival benefit is prioritized. Nevertheless, these rankings are mainly based on indirect comparisons and should be interpreted together with safety, patient characteristics, treatment accessibility, and other clinical considerations.
Our findings extend those of previous network meta-analyses of first-line treatment for aRCC. Su etĀ al. () included four randomized controlled trials and reported that pembrolizumab plus axitinib ranked favorably among the available ICI-based regimens in the overall population. In contrast, the present study incorporated seven phase III trials and included several more recently available ICI-targeted combinations, thereby providing an updated comparison of the current treatment landscape. In addition, whereas the previous economic evaluation was conducted from the US payer perspective, our analysis was performed from the perspective of the Chinese healthcare system, making the findings more directly relevant to clinical and reimbursement decision-making in China.
However, our cost-effectiveness analysis revealed a striking conflict between clinical efficacy and economic viability. Although toripalimab plus axitinib achieved the greatest gains in QALYs, its high drug cost resulted in an ICER exceeding the Chinese WTP threshold. These results are highly consistent with previous pharmacoeconomic studies on first-line immunotherapy combinations for aRCC (), which consistently concluded that none of the current first-line immune-targeted regimens are cost-effective under current pricing. Even though toripalimab plus axitinib showed the most favorable economic profile among all included strategies, its cost-effectiveness probability remained extremely low. Collectively, these findings reinforce that high treatment costs represent a major barrier to the widespread clinical adoption of these effective regimens, and clinical benefit alone cannot justify their extensive application in the Chinese healthcare setting.
This study has several limitations. First, the network meta-analysis was based on published aggregate data, and a fixed-effect model was employed due to network structure constraints, which may not have fully captured between-study heterogeneity. Second, cost data were primarily based on publicly listed prices and medical service fees in mainland China, which may not be generalizable to other regions or payment systems. Third, the model assumed that all patients received the same second-line therapy after disease progression, without considering the potential impact of subsequent treatment lines on long-term survival and economic outcomes. To further explore this uncertainty, scenario analyses using alternative subsequent-treatment assumptions were conducted, and the overall cost-effectiveness conclusions remained unchanged. Finally, the economic evaluation was not conducted for patient subgroups, among whom efficacy and resource consumption may differ.
5 Conclusion
Integrating findings from both the NMA and the cost-effectiveness analysis, this study concludes that for the first-line treatment of aRCC in China, toripalimab plus axitinib represents the most efficacious therapeutic strategy based on current evidence. However, from the perspective of the Chinese healthcare system, none of the evaluated regimens were deemed cost-effective at the WTP threshold of $40,332.35 per QALY gained. Although toripalimab plus axitinib demonstrated the lowest ICER and the highest cost-effectiveness probability among all strategies, its economic viability remains unestablished. Consequently, clinical decision-makers face a dilemma rather than a trade-off: while toripalimab plus axitinib offers the greatest clinical benefit, its current pricing imposes a substantial financial burden. It is suggested that price negotiations or patient assistance programs are urgently needed to bridge the gap between clinical efficacy and economic feasibility. Future real-world studies are warranted to further validate the long-term effectiveness and economic impact of these regimens.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Author contributions
YJ: Formal analysis, Methodology, Writing ā review & editing, Data curation, Writing ā original draft, Visualization. SZ: Supervision, Writing ā review & editing, Conceptualization, Project administration, Methodology. XW: Visualization, Formal analysis, Writing ā review & editing, Data curation. SK: Methodology, WritingĀ ā review & editing, Investigation, Project administration.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. Generative AI tools were used solely to assist with language editing, including improving grammar, clarity, and readability. All AI-assisted content was carefully reviewed and revised by the authors, who take full responsibility for the final manuscript. Generative AI was not used for data generation, data analysis, statistical analysis, interpretation of results, or formulation of scientific conclusions.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2026.1912070/full#supplementary-material
References
1
BrayFLaversanneMSungHFerlayJSiegelRLSoerjomataramIet al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229ā63. doi:Ā 10.3322/caac.21834
2
MotzerRJJonaschEAgarwalNAlvaABaineMBeckermannKet al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. (2022) 20:71ā90. doi:Ā 10.6004/jnccn.2022.0001
3
ZhengRSChenRHanBFWangSMLiLSunKXet al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. (2024) 46:221ā31. doi:Ā 10.3760/cma.j.cn112152-20240119-00035
4
MotzerRJHutsonTETomczakPMichaelsonMDBukowskiRMRixeOet al. Sunitinib versus interferon alfa in metastatic renal-cellcarcinoma. N Engl J Med. (2007) 356:115ā24. doi:Ā 10.1056/NEJMoa065044
5
SinghD. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. (2021) 264:118632. doi:Ā 10.1016/j.lfs.2020.118632
6
MoscettiLHennikPBolstadBCamareroJJosephsonFMelchiorriDet al. Combinations in the first-line treatment ofpatients with advanced/metastatic renal cell cancer: regulatory aspects. ESMO Open. (2020) 5:e000856. doi:Ā 10.1136/esmoopen-2020-000856
7
YanXQYeMJZouQChenPHeZSWuBet al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. (2024) 35:190ā9. doi:Ā 10.1016/j.annonc.2023.09.3108
8
MotzerRJEscudierBBurottoMPowlesTApoloABBourlonMTet al. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Ann Oncol. (2026) 37:33ā43. doi:Ā 10.1016/j.annonc.2025.09.006
9
PRISMA. (2022). Available online at: http://www.prisma-statement.org/ (Accessed March 1, 2026).
10
ChenJWangJXuH. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis. Med (Baltimore). (2021) 100:e25180. doi:Ā 10.1097/MD.0000000000025180
11
SuYFuJDuJWuB. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. Ther Adv Med Oncol. (2020) 12:1758835920950199. doi:Ā 10.1177/1758835920950199
12
HusereauDDrummondMAugustovskiFde Bekker-GrobEBriggsAHCarswellCet al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. J Manag Care Spec Pharm. (2022) 28:146ā55. doi:Ā 10.18553/jmcp.2022.28.2.146
13
LiuGHuSWuJWuJDongCLiH. China Guidelines for Pharmacoeconomic Evaluations. Beijing: China Market Press (2020).
14
PeiRShiYLvSDaiTZhangFLiuSet al. Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: A network meta-analysis and cost-effectiveness analysis. JAMA Netw Open. (2021) 4:e218065. doi:Ā 10.1001/jamanetworkopen.2021.8065
15
RoystonPParmarMKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. (2002) 21:2175ā97. doi:Ā 10.1002/sim.1203
16
HoyleMWHenleyW. Improved curve fits to summary survival data: Application to economic evaluation of health technologies. BMC Med Res Methodol. (2011) 11:139. doi:Ā 10.1186/1471-2288-11-139
17
KearnsBStevensonMDTriantafyllopoulosKMancaA. Generalized linear models for flexible parametric modeling of the hazard function. Med Decis Making. (2019) 39:867ā78. doi:Ā 10.1177/0272989x19873661
18
Chinese Society of Clinical Oncology (CSCO) Guidelines Working Committee. CSCO guidelines for the diagnosis and treatment of renal cell carcinoma (2023). Beijing, China: People's Medical Publishing House (2023).
19
WuBZhangQSunJ. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J Immunother Cancer. (2018) 6:124. doi:Ā 10.1186/s40425-018-0440-9
20
ThokalaPOchalekJLeechAATongT. Cost-effectiveness thresholds: The past, the present and the future. PharmacoEconomics. (2018) 36:509ā22. doi:Ā 10.1007/s40273-017-0606-1
21
National Healthcare Security Administration of ChinaMinistry of Human Resources and Social Security of China. National Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug Catalogue (2025). Beijing: National Healthcare Security Administration (2025). doi:Ā 10.32388/jtkb57
22
LuPLiangWLiJHongYChenZLiuTet al. A cost-effectiveness analysis: First-line avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. Front Pharmacol. (2020) 11:619. doi:Ā 10.3389/fphar.2020.00619
23
ZhuYLiuKDingDPengL. First-line lenvatinib plus pembrolizumab or everolimus versus sunitinib for advanced renal cell carcinoma: A United States-based cost-effectiveness analysis. Clin Genitourin Cancer. (2023) 21:417.e1ā417.e10. doi:Ā 10.1016/j.clgc.2022.11.014
24
DingBYaoHTaoTSunYZhuYZhuHet al. Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China. Ther Adv Med Oncol. (2025) 17:17588359251379708. doi:Ā 10.1177/17588359251379708
25
YingHTongFZhouYZhouBQiaoKChenLet al. A cost-effectiveness comparison between immunotherapy combination regimens and sunitinib for advanced renal cell carcinoma in the USA and China. Ther Adv Med Oncol. (2025) 17:17588359251385392. doi:Ā 10.1177/17588359251385392
26
WangHWangYLiLZhouHShangLLiaoLet al. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China. Front Public Health. (2022) 10:954264. doi:Ā 10.3389/fpubh.2022.954264
27
XuHWangLLouYQiuZXuanF. Benmelstobart plus anlotinib is unlikely to be cost-effective for advanced renal cell carcinoma: An integrated disease burden and cost-effectiveness analysis. Inquiry. (2026) 63:469580261440346. doi:Ā 10.1177/00469580261440346
28
MotzerRJPortaCEtoMPowlesTGrünwaldVHutsonTEet al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. (2024) 42:1222ā8. doi:Ā 10.1200/JCO.23.01569
29
ChoueiriTKPenkovKUemuraHCampbellMTPalSKollmannsbergerCet al. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. (2025) 36:387ā92. doi:Ā 10.1016/j.annonc.2024.12.008
30
ZhouAShenPLiJQuWWangZRenXet al. First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. (2025) 26:1145ā57. doi:Ā 10.1016/S1470-2045(25)00343-2
31
RiniBIPowlesTAtkinsMBEscudierBMcDermottDFSuarezCet al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. (2019) 393:2404ā15. doi:Ā 10.1016/S0140-6736(19)30723-8
32
RiniBIPlimackERStusVGafanovRWaddellTNosovDet al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat Med. (2025) 31:3475ā84. doi:Ā 10.1038/s41591-025-03867-5
Summary
Keywords
cost-effectiveness analysis, immunotherapy, network meta-analysis, renal cell carcinoma, targeted therapy
Citation
Jia Y, Zhao S, Wang X and Kang S (2026) First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis. Front. Immunol. 17:1912070. doi: 10.3389/fimmu.2026.1912070
Received
17 June 2026
Revised
15 August 2026
Accepted
03 September 2026
Published
30 September 2026
Volume
17 - 2026
Edited by
Myrna Candelaria, Hospital Angeles Pedregal, Mexico
Reviewed by
Yuyan Zhu, The First Affiliated Hospital of China Medical University, China
Mattia Alberto Di Civita, Sapienza University of Rome, Italy
Updates
Copyright
Ā© 2026 Jia, Zhao, Wang and Kang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shuo Kang, shuok628@hebmu.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.